Replies to post #141148 on Anavex Life Sciences Corp (AVXL)

[LakeshoreLeo1953]

Final paragraph seems to limit or burden biomarker
use at this time either for justification of results
or enrollment determinant.

did I go askew with that interpretation?

[frrol]

Hopefully. There's a number of more potent S1 agonists out there in use already, so that in itself isn't promising. I'm looking forward to dose related (real dose related, not BS) clinical improvement. The AD data so far is problematic, I have higher hopes for the RS trial.